Clinical Trials Logo

Diabetic Patients clinical trials

View clinical trials related to Diabetic Patients.

Filter by:
  • None
  • Page 1

NCT ID: NCT06079463 Not yet recruiting - Diabetic Patients Clinical Trials

The Effect of Progressive Relaxation Exercise on Anxiety and Quality of Life of Diabetic Patients

Start date: October 10, 2023
Phase: N/A
Study type: Interventional

Purpose of the study: The study aimed to direct the anxiety and quality of life of progressive movement exercise in diabetic patients. Type of research: A randomized controlled pre-test-post-test study was planned with the aim of directing progressive movement exercise on anxiety and quality of life in diabetics. research questions Q1: Does progressive movement exercise have an effect on diabetic anxiety and quality of life? Population of the Research and Sample Selection: The home of the research will be the diabetes windows to the internal service on data collection. G-power 3.1 analysis program environment to calculate large sample size. Sampling of the research; With 0.61% effect sizes, 0.05% error level, 95% confidence interval and 80% power to show the universe, 52 people took part in the experimental motivations (phased training exercises group) and 52 people took part in the control slots, for a total of 104 people. Sample selection criteria patients are randomized using the Random Integer Generator method from the Numbers subheading on the Random.org website. In randomization, aspects will be collected representatively of 1 experimental group and 2 control groups.

NCT ID: NCT06030544 Recruiting - Clinical trials for Type II Diabetes Mellitus

Oleanolic Acid as Therapeutic Adjuvant for Type 2 Diabetes Mellitus (OLTRAD STUDY)

OLTRAD
Start date: February 25, 2022
Phase: Phase 2
Study type: Interventional

Oleanolic acid (OA), is a natural component of many plant food and medicinal herbs, which has shown to exert in experimental models hypoglycemic and hypolipidemic effects, and also a cytoprotective action against oxidative and chemotoxic stress underlying Type II Diabetes Mellitus (T2DM).Today it is known that OA shares mechanisms of action with metformin and other drugs of choice for the treatment of diabetes. Therefore, the OLTRAD (OLeanolic acid TReAtment for type 2 Diabetes) Study, a prospective, parallel group, randomized, double-blind, controlled trial with 100 participants, has been designed to demonstrate that the regular intake of an OA-enriched functional olive oil is effective as an adjuvant to metformin antidiabetic drug therapy. The hypothesis is that the inclusion of this functional olive oil in the diet will enhance the effects of the pharmacological treatment in diabetic patients, and may even reduce the need for prescription of such medications.

NCT ID: NCT05791019 Not yet recruiting - Diabetic Patients Clinical Trials

Efficacy of Paleolithic Diet in Control of Blood Level of Glucose in Type 2 DM Patients

Start date: June 1, 2023
Phase:
Study type: Observational

Efficacy of paleolithic diet in control of blood glucose level in type 2 DM patients

NCT ID: NCT05681533 Recruiting - Diabetic Patients Clinical Trials

Epicardial Adipose Tissue and Arterial Stiffness in People Living With Diabetes (METAB-CV-PWV)

METAB-CV-PWV
Start date: March 31, 2021
Phase:
Study type: Observational

The present study is a retrospective and prospective current care cohort that will allow us to evaluate the relationship between epicardial fat volume and increased arterial stiffness in a person living with diabetes.

NCT ID: NCT03917940 Completed - Diabetic Patients Clinical Trials

Omega 3 Fatty Acids on Serum Irisin and Sirtuin-1 in Type 2 Diabetic Mellitus Patients Treated With Glimepiride

Start date: January 31, 2019
Phase: N/A
Study type: Interventional

study the effect of omega 3 fatty acids on blood glucose, lipids profile, serum Irisin and sirtuin-1 in type 2 diabetic mellitus patients treated with glimepiride.

NCT ID: NCT01972477 Withdrawn - Diabetic Patients Clinical Trials

DLBS1449 in Diabetic Patients With Low HDL

Start date: July 2016
Phase: Phase 2/Phase 3
Study type: Interventional

This is a parallel, 3-arm, randomized, prospective, placebo-controlled, and double-blind clinical study for eight weeks of therapy to investigate the clinical efficacy of DLBS1449 in elevating high density lipoprotein (HDL) cholesterol in diabetic patients. The hypothesis of interest for the study is: the administration of DLBS1449 will elevate HDL-cholesterol level from baseline to the end of study significantly higher than the elevation resulted by placebo. In addition, the administration of DLBS1449 at the dose of 150 mg daily will provide a significantly better response than that of the lower dose (DLBS1449 75 mg daily).

NCT ID: NCT01585792 Completed - Diabetic Patients Clinical Trials

Double Blind Comparative Study of TAK-875

Start date: May 2012
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of treatment with TAK-875 in diabetic patients.